Fulcrum Therapeutics, Inc. (FULC)
3.85
0.00 (0.00%)
USD |
NASDAQ |
Aug 28, 16:00
3.855
0.00 (0.00%)
After-Hours: 20:00
Fulcrum Therapeutics Debt to Equity Ratio : 0.017 for June 30, 2026
Debt to Equity Ratio Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Debt to Equity Ratio Data
| Date | Value |
|---|---|
| June 30, 2026 | 0.017 |
| March 31, 2026 | 0.0176 |
| December 31, 2025 | 0.0185 |
| September 30, 2025 | 0.0353 |
| June 30, 2025 | 0.0353 |
| March 31, 2025 | 0.0355 |
| December 31, 2024 | 0.0355 |
| September 30, 2024 | 0.0355 |
| June 30, 2024 | 0.0353 |
| March 31, 2024 | 0.0475 |
| December 31, 2023 | 0.046 |
| September 30, 2023 | 0.045 |
| June 30, 2023 | 0.0441 |
| March 31, 2023 | 0.0432 |
| December 31, 2022 | 0.0675 |
| September 30, 2022 | 0.0634 |
| Date | Value |
|---|---|
| June 30, 2022 | 0.0911 |
| March 31, 2022 | 0.0805 |
| December 31, 2021 | 0.00 |
| September 30, 2021 | 0.00 |
| June 30, 2021 | 0.00 |
| March 31, 2021 | 0.00 |
| December 31, 2020 | 0.0002 |
| September 30, 2020 | 0.0003 |
| June 30, 2020 | 0.0004 |
| March 31, 2020 | 0.0007 |
| December 31, 2019 | 0.0008 |
| September 30, 2019 | 0.0005 |
| June 30, 2019 | -1.479 |
| March 31, 2019 | -1.657 |
| December 31, 2018 | -2.196 |
Debt to Equity Ratio Definition
The debt to equity ratio measures the (Long Term Debt + Current Portion of Long Term Debt) / Total Shareholders' Equity. This metric is useful when analyzing the health of a company's balance sheet.
Debt to Equity Ratio Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Debt to Equity Ratio Benchmarks
| Cocrystal Pharma, Inc. | 1.284 |
| CNBX Pharmaceuticals, Inc. | -0.4388 |
| GB Sciences, Inc. | -- |
| Arvinas, Inc. | 0.0146 |
| Definium Therapeutics, Inc. | 0.0397 |
Debt to Equity Ratio Related Metrics
| Total Assets (Quarterly) | 323.95M |
| Total Liabilities (Quarterly) | 13.26M |
| Shareholders Equity (Quarterly) | 310.70M |
| Current Ratio | 31.35 |
| Net Debt Paydown Yield | 0.20% |